Review form Health Canada of nepafenac (Nevanac) , a non-steroidal anti-inflammatory drug (NSAID) for the management of pain and inflammation associated with cataract surgery
On April 17, 2008, Health Canada issued a Notice of Compliance to Alcon Canada Inc. for the drug product, NevanacTM (nepafenac) Ophthalmic Suspension.
NevanacTM contains the medicinal ingredient nepafenac which is a nonsteroidal
anti-inflammatory drug (NSAID).
NevanacTM is indicated for the management of pain and inflammation associated with cataract surgery. After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac. Amfenac inhibits the action of prostaglandin H synthase (cyclooxygenase), an enzyme required to produce prostaglandin which causes pain and swelling in the eye.